Compare ARK Genomic Revolution ETF (ARKG) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Credo Technology Group Holding Ltd — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Credo Technology Group Holding Ltd trades at $251.34 (market cap $48.07B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals.
| ARKG | CRDO | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $302.52 |
52-Week Low | $23.09 | $87.81 |
Market Cap | — | $48.07B |
Enterprise Value | — | $46.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
CRDO trades at $257.79, down 2.96% today but maintains strong bullish momentum with analyst consensus at 'Buy' (86.7% of 15 analysts). The stock shows robust fundamentals with 35.37% net income margin and triple-digit revenue growth projections for 2026. Recent earnings consistently beat expectations, and technical indicators suggest bullish momentum with support at $258 and resistance at $276.
Outlook remains positive given AI infrastructure demand and strong financial performance, though elevated valuations (P/E 102.7) and customer concentration risks warrant caution. The consensus price target of $273.33 implies 6% upside potential from current levels, supported by institutional optimism and expanding market opportunities in high-speed connectivity solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →
